Genmab A/S (GNMSF) Common Equity (2019 - 2026)
Genmab A's (GNMSF) quarterly Common Equity came in at $5.7 billion in Q1 2026, up 56720.0% YoY from N/an in Q1 2025, and down 2.82% on a QoQ basis from $5.8 billion in Q4 2025.
Genmab A/S (GNMSF) Common Equity (2019 - 2026) Analysis & Trends
Genmab A (GNMSF) has 5 years of Common Equity data on file, last reported at $5.7 billion in Q1 2026.
- Quarterly Common Equity rose 56720.0% year-over-year to $5.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 billion (up 56720.0% YoY) and the FY2025 annual result came in at $5.8 billion, up 13.82% from the prior year.
- Common Equity fell to $5.7 billion in Q1 2026, from $5.8 billion in the prior quarter.
- In the past five years, Common Equity ranged from a high of $5.8 billion in Q4 2025 to a low of $10.0 million in Q1 2024.
- A 3-year average of $3.6 billion and a median of $5.1 billion in 2024 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 57410.0% in 2025, down 0.0% in 2025.
- Tracing GNMSF's Common Equity over 3 years: stood at $5.1 billion in 2024, then advanced by 13.82% to $5.8 billion in 2025, then retreated by 2.82% to $5.7 billion in 2026.
- The last three Common Equity figures came in at $5.7 billion (Q1 2026), $5.8 billion (Q4 2025), and $5.8 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.68 Bn |
| Dec 31, 2025 | 5.85 Bn |
| Sep 30, 2025 | 5.75 Bn |
| Jun 30, 2025 | 5.30 Bn |
| Mar 31, 2025 | 10.00 Mn |
| Dec 31, 2024 | 5.14 Bn |
| Sep 30, 2024 | 10.00 Mn |
| Jun 30, 2024 | 4.45 Bn |
| Mar 31, 2024 | 10.00 Mn |
| Sep 30, 2020 | 18,477.00 |
| Dec 31, 2019 | 14,048.00 |
| Sep 30, 2019 | 12.51 Bn |